TPM4 and inflammatory myofibroblastic tumor: Moreover, the RNA-seq results refined the consensus diagnosis in 5 (11%) additional patients (Fig. 1), including SRF-NCOA1 in spindle cell rhabdomyosarcoma, MYOD1 p.L122R in sclerosing rhabdomyosarcoma, TPM4-ALK in inflammatory myofibroblastic tumor, and BCOR-CCNB3 in clear cell sarcoma of the kidney.